1 – 10 of 22
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
The Paintings Reveal the Story : Case Study of a Well-Known Swedish Artist Suffering from Alzheimer's Disease
(
- Contribution to journal › Article
- 2021
-
Mark
Predictors of mortality in patients with different apolipoprotein E genotypes—a 20-year follow-up of Alzheimer’s disease.
2021) 15th International Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2021)(
- Contribution to conference › Abstract
- 2020
-
Mark
The interaction effect of sex and apolipoprotein E genotype in Alzheimer’s disease—rates of progression and prognosis.
2020) Advances in Alzheimer's and Parkinson's Therapies (AAT-AD/PD) Focus Meeting 2020(
- Contribution to conference › Abstract
- 2019
-
Mark
Sex differences in predictors of mortality in patients with Alzheimer’s disease – A 20-year follow-up.
2019) 14th International Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2019)(
- Contribution to conference › Abstract
- 2017
-
Mark
The outcomes of different assessment scales can predict survival in patients with Alzheimer’s disease
2017) 13th International Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2017) In Neurodegenerative Diseases 17(Suppl. 1). p.27-27(
- Contribution to journal › Published meeting abstract
- 2016
-
Mark
Short-term response to cholinesterase inhibitors in Alzheimer’s disease delays time to nursing home placement.
2016) 14th International Athens/Springfield Symposium on Advances in Alzheimer Therapy In Neurobiology of Aging 39(Suppl. 1). p.2-2(
- Contribution to journal › Published meeting abstract
-
Mark
Cholinesterase inhibitors do not alter the length of stay in nursing homes among patients with Alzheimer's disease : A prospective, observational study of factors affecting survival time from admission to death.
(
- Contribution to journal › Article
- 2014
-
Mark
Response to cholinesterase inhibitors affects lifespan in Alzheimer's disease.
(
- Contribution to journal › Article
- 2013
-
Mark
Evaluation of the Cerebrospinal Fluid Amyloid-beta(1-42)/Amyloid-beta(1-40) Ratio Measured by Alpha-LISA to Distinguish Alzheimer's Disease from Other Dementia Disorders
(
- Contribution to journal › Article
- 2012
-
Mark
Altered CSF Orexin and α-Synuclein Levels in Dementia Patients.
(
- Contribution to journal › Article